Breast Cancer: Open Trials


ABCSG 41/OlympiA

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase-III-study to assess the efficacy and safety of olaparib vs. placebo as adjuvant treatment in patients with germline BRCA1/2-mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.



ABCSG 48/POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy.